Researchers conducted a 32,000-participant, randomized controlled clinical trial, called FIM12. Researchers performed a cost-utility analysis from a Canadian healthcare perspective. Additionally, they mapped clinical illness data from the trial to quality-of-life data.
Researchers found that average per-participant medical costs were $47 lower for the high-dose inactivated influenza vaccine group. Societal costs were $60 lower in the same group.
Hospitalizations accounted for 91 percent of the total cost and were less frequent in the high-dose inactivated influenza vaccine group. In Canada, high-dose inactivated influenza vaccine is expected to be a less costly and more effective alternative to standard-dose vaccine, driven by a reduction in hospitalizations.
More articles on healthcare quality:
Bloodstream infection clusters across 3 states may be associated with central lines
Readmissions past 7 days may be out of hospitals’ control, study finds
Lower heart rates reduce risk of death among septic shock patients: 4 insights
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
